More info
Active ingredients
Fluconazole
Release form
Gel
Composition
1 g of gel contains: Active substance: Fluconazole - 5.0 mg. Adjuvants: propylene glycol - 10 mg, methyl parahydroxybenzoate -1.8 mg, propyl parahydroxybenzoate - 0.2 mg, disodium edetate - 0.5 mg, macrogol 400 -50 mg, carbomer - 10 mg, diethylamine to pH 6.0 - 7.0, purified water to 1.00 g
Pharmacological effect
Antifungal agent from the group of triazole derivatives. Inhibits the synthesis of ergosterol, violating the permeability of the cell wall. Active against Candida, Microsporum, Cryptococcus neoformans, Trichophyton
Pharmacokinetics
When applied externally, it is practically not absorbed from the skin surface and does not have a systemic effect.
Indications
Cryptococcosis, including cryptococcal meningitis and infections of other localization (for example, lungs, skin), including in patients with a normal immune response and in patients with AIDS, recipients of transplanted organs and patients with other forms of immunodeficiency; supportive therapy to prevent the recurrence of cryptococcosis in AIDS patients. Generalized candidiasis, including candidaemia, disseminated candidiasis and other forms of invasive candidal infection, such as infections of the peritoneum, endocardium, eyes, respiratory and urinary tract, including in patients with malignant tumors who are in ICUs and are receiving cytotoxic or immunosuppressive agents, as well as in patients with other factors predisposing to the development of candidiasis. Candidiasis of the mucous membranes, including mucous membranes of the oral cavity and pharynx, esophagus, non-invasive broncho-pulmonary infections, candiduria, skin - mucous and chronic atrophic candidiasis of the oral cavity (associated with the wearing of dental prostheses), including in patients with normal and suppressed immune function; prevention of recurrent oropharyngeal candidiasis in AIDS patients. Genital candidiasis; acute or recurrent vaginal candidiasis; prevention to reduce the frequency of recurrences of vaginal candidiasis (3 or more episodes per year); Candida balanitis. Mycoses of the skin, including mycoses of the feet, body, inguinal region, pityriasis versicolor, onychomycosis, and skin candidal infections. Deep endemic mycoses in patients with normal immunity, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis, and histoplasmosis. predisposed to the development of such infections as a result of cytotoxic chemotherapy or radiation therapy
Contraindications
Increased sensitivity to components of the drug, including to other azole compounds in the anamnesis
Precautionary measures
Apply after consulting a doctor
Use during pregnancy and lactation
Contraindicated
Dosage and administration
Flucore is applied externally: the gel is applied to the affected area with a thin even layer, also grabbing 2 cm and the adjacent area, and rubbing it until completely absorbed 2 times a day (morning and evening). Duration of use is 1 - 3 weeks depending on the pathogen and the place of its manifestation. In some resistant forms, the duration of use can be extended up to 6 weeks as recommended by a doctor.
Side effects
Local reactions are rarely observed: skin irritation, burning sensation. Allergic reactions are possible (urticaria, skin rash)
Overdose
No information
Interaction with other drugs
Clinically significant drug interaction with Flucorrem with other drugs not established
special instructions
The drug is not intended for use in ophthalmology. Avoid contact with eyes. In the absence of the effect of therapy within a specified time, it is necessary to revise the diagnosis. When the first symptoms of hypersensitivity or skin irritation appear, the drug should be discontinued. Without consulting a doctor, do not use with other drugs for local use. Flucor does not affect the ability to drive vehicles and work that requires high concentration of attention and speed of psychomotor reactions